• Novelos Therapeutics Inc., of Madison, Wis., named Rock Mackie, John Neis, John Niederhuber, Michael Tweedle and Jamey Weichert to the board.

• Numerate Inc., of San Bruno, Calif., appointed David Jobes senior vice president of business and corporate development.

• OncoSec Medical Inc., of San Diego, appointed Michael Cross chief business officer, Caryn Peterson vice president of regulatory affairs and Veronica Vallejo controller and principal financial officer.

• Optimer Pharmaceuticals Inc., of San Diego, appointed Nancy Ruiz senior vice president of R&D, named Cynthia Schwalm senior vice president of international and added Kasia Petchel as senior vice president of pharmacovigilance.

• Pevion Biotech AG, of Bern, Switzerland, named Jean-Paul Prieels to its board.

• PhaseBio Pharmaceuticals Inc., of Malvern, Pa., appointed Kathryn J. Gregory vice president of business development.

• Prexa Pharmaceuticals Inc., of Boston, appointed Scott Reines chief medical officer and named Evelyn Graham chief operating officer.

• Protect Pharmaceutical Corp., of Princeton, N.J., appointed Ramesha Sesha CEO and chairman.

• Proteostasis Therapeutics Inc., of Cambridge, Mass., named Alfred Goldberg and Daniel Finley scientific co-founders.

• Raptor Pharmaceutical Corp., of Novato, Calif., named Kathlene L. Powell vice president of quality operations. It also appointed Suzanne L. Bruhn, Vijay B. Samant and Timothy P. Walbert to its board.

• Regulus Therapeutics Inc., of La Jolla, Calif., appointed Neil Gibson chief scientific officer.

• Savient Pharmaceuticals Inc., of East Brunswick, N.J., named Richard Crowley executive vice president of biopharmaceutical operations.

• Seattle Genetics Inc., of Bothell, Wash., appointed Natasha Hernday vice president of corporate development and promoted Eric Sievers vice president of clinical affairs.

• Sirona Biochem Corp., of Vancouver, British Columbia, appointed Stuart Maddin to its scientific advisory board.

• SymBio Pharmaceuticals Ltd., of Tokyo, added Abel Riera Corominas as director of business development.

• Symphogen AG, of Copenhagen, Denmark, added Ivan D. Horak as chief scientific/medical officer and Gayle M. Mills as chief business officer. The firm also elected four new members to its board: Sam Broder, John B. Landis, Jeppe Christiansen and Tom Bork Petersen.

• Yaupon Therapeutics Inc., of Radnor, Pa., appointed Steve Tullman chairman and CEO.

• Zealand Pharma A/S, of Copenhagen, Denmark, elected Jutta af Rosenborg and Jorgen Lindegaard to its board.